27 results on '"Motoya, Satoshi"'
Search Results
2. Association of ulcerative colitis symptom severity and proctocolectomy with multidimensional patient-reported outcomes: a cross-sectional study
3. Safety and Effectiveness of Vedolizumab in Patients with Moderate-to-Severe Ulcerative Colitis: An Interim Analysis of a Japanese Post-Marketing Surveillance Study
4. Anxiety and behavioral changes in Japanese patients with inflammatory bowel disease due to COVID-19 pandemic: a national survey
5. Characteristics of adult patients newly diagnosed with Crohn’s disease: interim analysis of the nation-wide inception cohort registry study of patients with Crohn’s disease in Japan (iCREST-CD)
6. Correction: Characteristics of adult patients newly diagnosed with Crohn’s disease: interim analysis of the nation-wide inception cohort registry study of patients with Crohn’s disease in Japan (iCREST-CD)
7. A nationwide survey concerning the mortality and risk of progressing severity due to arterial and venous thromboembolism in inflammatory bowel disease in Japan
8. Adrenomedullin for steroid-resistant ulcerative colitis: a randomized, double-blind, placebo-controlled phase-2a clinical trial
9. Effects of vedolizumab in Japanese patients with Crohn’s disease: a prospective, multicenter, randomized, placebo-controlled Phase 3 trial with exploratory analyses
10. Withdrawal of thiopurines in Crohn’s disease treated with scheduled adalimumab maintenance: a prospective randomised clinical trial (DIAMOND2)
11. NUDT15 codon 139 is the best pharmacogenetic marker for predicting thiopurine-induced severe adverse events in Japanese patients with inflammatory bowel disease: a multicenter study
12. Postoperative therapy with infliximab for Crohn’s disease: a 2-year prospective randomized multicenter study in Japan
13. Evidence-based clinical practice guidelines for inflammatory bowel disease
14. Safety and effectiveness of granulocyte and monocyte adsorptive apheresis in patients with inflammatory bowel disease in special situations: a multicentre cohort study
15. Four-year maintenance treatment with adalimumab in Japanese patients with moderately to severely active ulcerative colitis
16. Genetic characteristics of inflammatory bowel disease in a Japanese population
17. First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis—results from a multicenter prospective randomized controlled trial and its post hoc analysis
18. Disease susceptibility genes shared by primary biliary cirrhosis and Crohn’s disease in the Japanese population
19. Risk factors for surgical site infection in Japanese patients with ulcerative colitis: a multicenter prospective study
20. Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis
21. C-reactive protein is an indicator of serum infliximab level in predicting loss of response in patients with Crohn’s disease
22. Therapeutic Efficacy of Infliximab on Patients with Short Duration of Crohn’s Disease: A Japanese Multicenter Survey
23. Association of SLC22A4/5 Polymorphisms with Steroid Responsiveness of Inflammatory Bowel Disease in Japan
24. Erratum to: Four-year maintenance treatment with adalimumab in Japanese patients with moderately to severely active ulcerative colitis
25. Adsorptive granulocyte and monocyte apheresis for refractory Crohn’s disease: an open multicenter prospective study
26. Rapidly growing early gastric cancer with microsatellite instability
27. Prevalence of Barrett's esophagus and expression of mucin antigens detected by a panel of monoclonal antibodies in Barrett's esophagus and esophageal adenocarcinoma in Japan
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.